MAHA loves dietary supplements. But that hasn't led to gains in Washington — yet.

Despite HHS Secretary Robert F. Kennedy Jr.'s personal advocacy and the administration's "Make America Healthy Again" initiative, the $69 billion U.S. dietary supplement industry has achieved no significant policy concessions. Manufacturers face ongoing challenges from strict FDA regulations on health claims and new import tariffs, while their lobbying efforts for broader market access and federal program coverage have yielded minimal results. Although industry leaders perceive a "window of opportunity" due to ongoing dialogue, tangible policy support remains elusive, highlighting a disconnect between political rhetoric and concrete action.

Analysis

The $69 billion U.S. dietary supplement industry is facing a significant disconnect between perceived political alignment with the current administration and the lack of tangible policy progress. Despite HHS Secretary Robert F. Kennedy Jr.'s personal enthusiasm for supplements, the sector has not secured key objectives such as relaxed FDA rules on health claims or the inclusion of supplements in tax-advantaged health savings accounts. Instead, the industry is contending with new operational headwinds, including import tariffs that disrupt supply chains for key ingredients sourced from China, India, and Europe. Furthermore, the administration's move to scrutinize the FDA's "generally recognized to be safe" (GRAS) pathway introduces regulatory uncertainty that could stifle innovation. This environment is creating internal fractures, with some industry players advocating for deregulation while others, like NOW Health Group, are calling for stricter FDA enforcement on low-quality products, particularly those sold on platforms like Amazon (AMZN). While industry leaders express cautious optimism about a "window of opportunity," the prevailing reality is one of policy stagnation and mounting operational challenges, creating an unpredictable outlook for growth.

Key Decisions for Investors

• Investors in the supplement sector should moderate expectations for near-term growth driven by deregulation and instead focus on companies with robust, diversified supply chains capable of mitigating tariff impacts.
• Closely monitor any policy shifts related to the FDA's GRAS framework and health claim regulations, as changes could significantly alter the competitive landscape, R&D costs, and marketing capabilities for manufacturers.
• For those with exposure to e-commerce, note the specific regulatory and reputational risk for platforms like Amazon, as increased calls for FDA enforcement on third-party sellers could lead to higher compliance costs and impact sales in the supplement category.